Journal of Nutrition EB Program 2010 Abstracts

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Nutrition, doi:10.3945/jn.108.099127
Vol. 138, No. 12, 2481-2486, December 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplemental Material
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lecleire, S.
Right arrow Articles by Coëffier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lecleire, S.
Right arrow Articles by Coëffier, M.
© 2008 American Society for Nutrition


Nutritional Immunology

Combined Glutamine and Arginine Decrease Proinflammatory Cytokine Production by Biopsies from Crohn's Patients in Association with Changes in Nuclear Factor-{kappa}B and p38 Mitogen-Activated Protein Kinase Pathways1–3,

Stéphane Lecleire4–6, Aktham Hassan4,6, Rachel Marion-Letellier4, Michel Antonietti5, Guillaume Savoye4,5, Christine Bôle-Feysot4, Eric Lerebours4,5, Philippe Ducrotté4,5, Pierre Déchelotte4,* and Moïse Coëffier4

4 Appareil Digestif Environnement Nutrition EA4311, Institute for Biomedical Research, IFRMP23, Rouen University and Rouen University Hospital, Rouen, France and 5 Department of Gastroenterology and Nutrition, Rouen University Hospital, Rouen, France

Glutamine (Gln) and arginine (Arg) are conditionally essential amino acids with immunomodulatory properties. The aim of the study was to assess the effects of Gln and Arg alone or in combination on cytokine release by cultured colonic biopsies from patients with active Crohn's disease (CD). Ten consecutive patients [mean (range) age 26 (18–39) y] with active colonic CD (mean CD activity index: 383.7 ± 129.8) were prospectively included in the study. Eight colonic biopsies were obtained via a colonoscopy and incubated during 18 h with low (physiological) or high (pharmacological) doses of Arg (0.1 or 2 mmol/L designated as Arglow or Arghigh, respectively) and Gln (0.6 or 10 mmol/L designated as Glnlow or Glnhigh, respectively). The concentrations of cytokines [interleukin (IL)-4, IL-10, IL-8, IL-6, tumor necrosis factor-{alpha} (TNF{alpha}), IL-1β, interferon-{gamma}) were assessed by ELISA, and nitric oxide (NO) production was evaluated by Griess assay. Nuclear factor (NF)-{kappa}B p65 subunit, inhibitor of NF{kappa}B-{alpha}, and p38 mitogen-activated protein kinase (MAPK) were assessed by immunoblotting. Arghigh/Glnhigh decreased the production of TNF{alpha}, IL-1β, IL-8, and IL-6 (each P < 0.01). Arglow/Glnhigh decreased IL-6 and IL-8 production (both P < 0.01), whereas Arghigh/Glnlow did not affect cytokine and NO production. Arglow/Glnhigh and Arghigh/Glnhigh decreased NF-{kappa}B p65 subunit expression, whereas p38 MAPK was decreased only by Arghigh/Glnhigh. Combined pharmacological doses of Arg and Gln decreased TNF{alpha} and the main proinflammatory cytokines release in active colonic CD biopsies via NF-{kappa}B and p38 MAPK pathways. These results could be the basis of prospective studies evaluating the effects of enteral supply of combined Arg and Gln during active CD.


* To whom correspondence should be addressed. E-mail: pierre.dechelotte{at}chu-rouen.fr.

Manuscript received 3 September 2008. Initial review completed 24 September 2008. Revision accepted 29 September 2008.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2008 by American Society for Nutrition